HMNC Brain Health reports Phase 2b efficacy signals for BH-200 in genetically defined depression patients at ACNP
Find out how HMNC Brain Health’s Phase 2b BH-200 data at ACNP reveal genetic responder signals that could advance precision psychiatry in depression treatment.